SoFi CEO enters prepaid forward contract on 1.5 million shares
Kamada Ltd (NASDAQ:KMDA). (Market cap: $385.43M), a pharmaceutical company specializing in the development and production of plasma-derived protein therapeutics, has declared a special cash dividend and reported its financial results for the year 2024. Today, the company affirmed its guidance for 2025, signaling continued double-digit profitable growth. According to InvestingPro data, the company maintains excellent financial health with a "GREAT" overall score of 3.48 out of 5.
The Israel-based company announced a special dividend of $0.20 per share, a move that reflects confidence in its financial stability and commitment to delivering value to shareholders. This declaration follows Kamada’s record financial performance for the year ended December 31, 2024. The company’s strong financial position is evidenced by its impressive current ratio of 4.84 and minimal debt-to-equity ratio of 0.04, as reported by InvestingPro.
Kamada’s financial results showcased significant top and bottom-line growth, with EBITDA reaching $29.42M in the last twelve months. The company attributes this performance to the successful execution of its strategic initiatives and the strong demand for its product portfolio. While specific financial figures were not disclosed in the press release, the announcement of record results indicates a period of robust earnings and operational efficiency. Based on InvestingPro’s Fair Value analysis, the stock currently appears to be trading near its fair value, with analysts setting price targets ranging from $11 to $20 per share.
Looking ahead, Kamada’s reaffirmation of its 2025 guidance suggests that the company expects to maintain its growth trajectory, with revenue growth forecast at 15% for FY2024. The guidance is based on the continued success of existing products and the potential introduction of new products and market expansions. For deeper insights into Kamada’s growth potential and comprehensive analysis, investors can access the detailed Pro Research Report available exclusively on InvestingPro.
The company’s recent achievements are being incorporated by reference into Kamada’s Form S-8 Registration Statements, demonstrating the relevance of these results to ongoing regulatory and investor considerations.
Kamada’s announcement is based on a press release statement filed with the United States Securities and Exchange Commission as a Report of Foreign Private Issuer on Form 6-K. The report provides investors with timely and accurate information about the company’s financial health and future outlook.
Investors and stakeholders in the pharmaceutical industry may view Kamada’s declaration of a special dividend and its positive financial results as indicators of the company’s strong market position and its ability to generate shareholder value. As Kamada continues to navigate the competitive landscape of pharmaceutical preparations, its performance will be closely monitored by the market.
In other recent news, Kamada Ltd. has announced that it will release its financial results for the fourth quarter and fiscal year 2024 on March 5, 2025. Investors are keenly awaiting this report, which will provide insights into the company’s financial performance over the past year. Additionally, Kamada Ltd. has secured a significant contract valued at $25 million for the supply of its products in Latin America. This three-year agreement involves the provision of KAMRAB® and VARIZIG® to undisclosed parties, reflecting the company’s expanding global reach. The announcement was made through a Form 6-K filing with the U.S. Securities and Exchange Commission. These developments highlight Kamada’s ongoing efforts to strengthen its position in the pharmaceutical preparations industry. Investors and stakeholders may view the Latin American contract as a positive indicator of Kamada’s business prospects. The company’s Vice President General Counsel and Corporate Secretary, Nir Livneh, confirmed the accuracy of this information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.